Literature DB >> 2002687

Chromosome studies in 104 patients with polycythemia vera.

J L Diez-Martin1, D L Graham, R M Petitt, G W Dewald.   

Abstract

Chromosome studies were done in 104 patients with various stages of polycythemia vera (PV): 10 had leukemia-myelodysplastic syndrome, 28 had post-PV with myeloid metaplasia (PPVMM), 12 had PV with myelofibrosis, and 54 had PV. Chromosome studies were successful in 86 patients, 37 (43%) of whom had a chromosome abnormality. At diagnosis, 4 of 28 patients (14%) had an abnormal clone; the incidence was 78% in PPVMM and 100% in leukemia-myelodysplastic syndrome. Among the 63 patients with successful chromosome studies during the first 10 years of disease, 27% had an abnormal clone. In contrast, of the 23 patients who had the disease for more than 10 years, 87% had an abnormal clone. Chromosome abnormalities were found in 11 of the 60 patients who either were untreated or underwent only phlebotomy and in 26 of the 44 patients who were treated with myelosuppressive agents. Trisomy 8, +9, and 20q- were found in some patients early during the course of their disease and also among untreated patients. These chromosome abnormalities seem to be related to the natural course of PV rather than to therapy. Patients with a chromosomally abnormal clone at the time of diagnosis of PV had a poorer survival than did those with only normal metaphases. Cytogenetic results did not predict evolution of the disease, but they did provide clues to hematologic phenotype, duration of the disease, and consequences of myelosuppressive therapy.

Entities:  

Mesh:

Year:  1991        PMID: 2002687     DOI: 10.1016/s0025-6196(12)61011-8

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  14 in total

1.  Localization of phospholipase C-gamma 1 to mouse chromosome 2.

Authors:  K K Nelson; J L Knopf; L D Siracusa
Journal:  Mamm Genome       Date:  1992       Impact factor: 2.957

2.  Diagnosis of polycythaemia.

Authors:  M Messinezy; T C Pearson
Journal:  J Clin Pathol       Date:  1998-01       Impact factor: 3.411

3.  A case of myelodysplastic syndrome with a der(1;18)(q10;q10) translocation.

Authors:  Jung-Sook Ha; Dong-Suk Jeon
Journal:  Blood Res       Date:  2014-06-25

Review 4.  JAK2 V617F in myeloid disorders: molecular diagnostic techniques and their clinical utility: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology.

Authors:  David P Steensma
Journal:  J Mol Diagn       Date:  2006-09       Impact factor: 5.568

Review 5.  A refined diagnostic algorithm for polycythemia vera that incorporates mutation screening for JAK2(V617F).

Authors:  Ayalew Tefferi
Journal:  Curr Hematol Malig Rep       Date:  2006-06       Impact factor: 3.952

6.  A Rare Presentation of Extramedullary Hematopoiesis in Post-polycythemic Myelofibrosis.

Authors:  Ceyla Konca Degertekin; Zübeyde Nur Ozkurt; Nalan Akyürek; Münci Yağcı
Journal:  Indian J Hematol Blood Transfus       Date:  2012-12-07       Impact factor: 0.900

Review 7.  Investigation of patients with polycythaemia.

Authors:  T C Pearson; M Messinezy
Journal:  Postgrad Med J       Date:  1996-09       Impact factor: 2.401

8.  A novel chromosomal abnormality, t(6;10)(q27;q22), found in a polycythemic potential donor for allogeneic hematopoietic stem cell transplantation.

Authors:  Hideki Mitsui; Norimitsu Saito; Atsushi Satake; Tsuyoshi Nakazawa; Takahiro Karasuno; Akira Hiraoka
Journal:  Int J Hematol       Date:  2005-07       Impact factor: 2.490

9.  Significance of cytogenetic abnormalities in patients with polycythemia vera.

Authors:  Matjaz Sever; Alfonso Quintás-Cardama; Sherry Pierce; Lingsha Zhou; Hagop Kantarjian; Srdan Verstovsek
Journal:  Leuk Lymphoma       Date:  2013-04-17

10.  The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course.

Authors:  Constantine S Tam; Lynne V Abruzzo; Katherine I Lin; Jorge Cortes; Alice Lynn; Michael J Keating; Deborah A Thomas; Sherry Pierce; Hagop Kantarjian; Srdan Verstovsek
Journal:  Blood       Date:  2009-01-08       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.